Skip to content

Multicenter randomized controlled study of retinoic acid cream to prevent and reduce hyperplastic scars

Multicenter randomized controlled study of retinoic acid cream to prevent and reduce hyperplastic scars - Multicenter randomized parallel controlled clinical trial of retinoic acid cream and silicone gel to prevent hypertrophic scars

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097242
Enrollment
Unknown
Registered
2025-02-14
Start date
2024-02-04
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperplastic scar

Interventions

Retinoic acid group (Group A):Apply retinoic acid cream to the healed surgical incision twice a day for three months.
Silicone scar gel (Group B):Apply silicone scar gel to the healed surgical incision twice a day for three months.

Sponsors

the First Affiliated Hospital of Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Patients aged 12-75 years after trauma and surgery; 2) Type-I incisions and type-II non-infectious Class A healing linear incisions on the trunk and extremities include: Neck thyroid surgery incision, breast cancer, breast reconstruction, giant mastectomy, breast prosthesis implantation (areolar incision, submammary fold incision), rib nose incision, donor skin and flap incision, abdominal wall molding wound, spine and limb post-operative wound, closed fracture of the trunk, benign and malignant tumors, spine and limb post-operative wound, closed fracture of the trunk, Benign and malignant tumors, thoracotomy incisions, abdominal non-infectious incisions, such as benign tumors, transplant surgery; 3) Subjects fully understand the research purpose and protocol of this study; 4) The subjects are willing to take the test and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients younger than 5 years and older than 75 years; 2) Patients at the end of their disease who may be lost to follow-up; 3) Subjects with clear scar constitution and pathological scar history; 4) Subjects diagnosed with scleroderma; 5) Class III incision; 6) The incision develops into a chronic wound; 7) There are benign and malignant diseases that affect the physiological state of the skin; 8) Have A clear history of allergy and adverse reactions to silicone and retinoic acid; 9) Pregnant and lactating women; 10) Incorporate other treatments that may affect the results, such as lasers.

Design outcomes

Primary

MeasureTime frame
Whether there was hypertrophic scar 3 months after the operation;

Secondary

MeasureTime frame
Whether hypertrophic scars occurred after 1 or 2 months of postoperative medication;The thickness of hypertrophic scar protruding from body surface thickness after 1, 2,3 months of postoperative medication;Vancouver Scale scores of hypertrophic scars 1, 2,3 months after treatment;POSAS scale score of hypertrophic scar 1, 2,3 months after treatment;

Countries

China

Contacts

Public ContactBaoqiang Song

The First Affiliated Hospital of Air Force Military Medical University

songbq2012@163.com+86 188 2902 5566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026